ClinicalTrials.gg
RecruitingNCT06932562Updated Mar 25, 2026

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

A Phase 3 interventional study of Linvoseltamab and Daratumumab in Multiple Myeloma, sponsored by European Myeloma Network B.V.. Recruiting at 59 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by European Myeloma Network B.V. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Planned enrollment
Largest of 16
1,000 · median 168
Started
2025
with 1 other
Phase 3
4 of 16
4 open now
Primary completion
2036-12
later than 14 of 14 live
Registered
9th of 16
by date
Lead sponsor
1 of 16
European Myeloma Network B.V.

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 14 of the 14 other live ones, and was the 9th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible).

The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma (MM)
  • Transplant ineligible
  • Newly diagnosed
  • Linvoseltamab
  • BCMA X CD3 bispecific antibody
  • CD38 antibody
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.
  2. Participants must not be considered a candidate for high-dose chemotherapy (HDT) and , as described in the protocol.
  3. Participants must have as defined in the protocol.
  4. (ECOG) performance status of 0, 1, or 2.
  5. Participants must have clinical laboratory values within a prespecified range.

Exclusion criteria

Exclusion Criteria:

  1. International Myeloma Working Group Frailty Index of 2 with the exception of participants who have a score of 2 based on age alone.
  2. Participants who defer transplant due to personal preference.
  3. Participants with non-secretory MM, active plasma cell leukemia, known light-chain (AL) amyloidosis in the presence of a concurrent diagnosis of myeloma, any other form of amyloidosis, Waldenström macroglobulinemia, or known POEMS syndrome.
  4. Any prior therapy for monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or MM, with the exception of:

    • focal radiation and/or
    • a short course of as defined in the protocol.
  5. Participants who have received or are receiving any agent or cell therapy with known or suspected activity against MM
  6. Participants who have known central nervous system (CNS) or meningeal involvement with MM or known or suspected progressive multifocal leukoencephalopathy (PML), a history of a neurocognitive condition or CNS movement disorder, OR a history of seizure, (TIA), stroke or seizure within 12 months prior to study C1D1.
  7. Participants who have uncontrolled intercurrent illness.
  8. Known to the use of daratumumab or lenalidomide per local prescribing information.
  9. History of hematopoietic stem cell transplantation or solid organ transplant at any time.

NOTE Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Control arm DRd

    Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Experimental Arm DRd+ linvolsetamab

    Drug: Linvoseltamab · Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Minimal Residual Disease (MRD)

    Minimal Residual Disease (MRD) negative Complete Remission (CR) status at 10\^-5 per International Myeloma Working Group (IMWG) criteria

    Time frame: up to 11 years

  2. MRD negative CR status by BICR

    MRD negative CR status at 10\^-5 as determined by the Blinded Independent Central Review (BICR)

    Time frame: up to 11 years

  3. Progression Free Survival (PFS) per IMWG criteria

    defined as the time from the date of randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier, where disease progression is determined per IMWG criteria.

    Time frame: up to 11 years

  4. PFS as determined by BICR

    defined as the time from the date of randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier, where disease progression is determined per by BICR.

    Time frame: up to 11 years

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS), measured from the date of from randomization to the date the subject's death

    Time frame: up to 11 years

  2. Objective Response (OR) of Complete Response (CR)

    To compare the proportion of patients who achieve an objective response per International Myeloma Working Group (IMWG) response criteria between the two study arms for Complete Response (CR) or better

    Time frame: up to 11 years

  3. OR of Very Good Partial Response (VGPR)

    To compare the proportion of patients who achieve an objective response per International Myeloma Working Group (IMWG) response criteria between the two study arms for VGPR or better

    Time frame: up to 11 years

  4. OR of Partial Response (PR)

    To compare the proportion of patients who achieve an objective response per International Myeloma Working Group (IMWG) response criteria between the two study arms for PR or better

    Time frame: up to 11 years

  5. Sustained MRD

    Sustained MRD negative CR (sMRD) at 10\^-5 per IMWG criteria

    Time frame: up to 11 years

  6. Duration of response (DOR) of stringent (s)CR

    duration of response to best overall response of stringent sCR, per IMWG response criteria

    Time frame: up to 11 years

  7. Duration of response (DOR) of CR

    duration of response to best overall response of CR, per IMWG response criteria

    Time frame: up to 11 years

  8. Duration of response (DOR) of VGPR

    duration of response to best overall response of VGPR, per IMWG response criteria

    Time frame: up to 11 years

  9. Duration of response (DOR) of PR

    duration of response to best overall response of PR, per IMWG response criteria

    Time frame: up to 11 years

  10. Time to response ≥CR

    Time from randomization to objective response (≥CR) as per IMWG response criteria

    Time frame: up to 11 years

  11. Time to response ≥VGPR

    Time from randomization to objective response (≥VGPR) as per IMWG response criteria

    Time frame: up to 11 years

  12. Time to response ≥PR

    Time from randomization to objective response (≥PR) as per IMWG response criteria

    Time frame: up to 11 years

  13. Disease progression

    Time to disease progression per IMWG response criteria

    Time frame: up to 11 years

  14. Incidence of TEAEs

    Incidence of treatment emergent adverse events (TEAEs)

    Time frame: up to 11 years

  15. Severity of TEAEs

    Severity of treatment emergent adverse events (TEAEs)

    Time frame: up to 11 years

  16. Serious Adverse Events

    Incidence of Serious Adverse Events (SAE)

    Time frame: up to 11 years

  17. Concentrations of linvoseltamab

    Concentrations of linvoseltamab in serum over time

    Time frame: up to 11 years

  18. Incidence antidrug antibodies

    Incidence of antidrug antibodies (ADAs) to linvoseltamab

    Time frame: up to 11 years

  19. Titer of ADA

    Titer of ADA to linvoseltamab

    Time frame: up to 11 years

  20. EORTC QLQ-C30 Global Health Status / Quality of Life

    Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported quality of life using one global health status/quality of life (GHS/QoL) scale, 5 functioning scales (physical, role, emotional, cognitive, and social) ranging from from 1 = "very poor" to 7 = "excellent" and 9 symptom scales/items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer, ranging from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

    Time frame: up to 11 years

  21. EORTC QLQ-C30 Physical Functioning (PF)

    Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire functioning scale Physical Functioning (PF). PF scale consist of 5 items, ranging from from 1 = "not at all" to 4 = "very much" higher scores indicate higher ("better") level of functioning

    Time frame: up to 11 years

  22. EORTC QLQ-C30 Role Functioning (RF)

    Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire functioning scale Role Functioning (RF). RF scale consist of 2 items, ranging from from 1 = "not at all" to 4 = "very much" higher scores indicate higher ("better") level of functioning

    Time frame: up to 11 years

  23. EORTC QLQ-C30 Pain

    Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire symptom scale Pain. Pain scale consist of 2 items, ranging from from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden

    Time frame: up to 11 years

  24. EORTC QLQ-C30 Fatigue

    Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire symptom scale Fatigue. Fatigue scale consist of 3 items, ranging from from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden

    Time frame: up to 11 years

  25. EQ-5D-5L VAS

    Change in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (EQ-5D-5L VAS). The EQ-5D-5L is a generic questionnaire that measures Health-Related Quality of Life (HRQoL) across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) across 5 levels (1= no problems, 2= slight problems, 3= some problems, 4= severe problems and 5= extreme problems), higher scores indicate lower health states And a visual analogue scale (VAS). VAS scale ranging from 0 = "worst" to 100 = "best" higher score indicate higher health status

    Time frame: up to 11 years

07

Study locations

59 of 59 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2036, 132 months after the start.

Of 72 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's planned 132 months is above that.

Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 17, 2025
StartActual
Dec 23, 2025
Primary completionEst.
Dec 2036
CompletionEst.
Dec 2036
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06932562
Lead sponsor
European Myeloma Network B.V.
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Dec 23, 2025
Primary completion
Dec 2036 (estimated)
Completion
Dec 2036 (estimated)
Last update
Mar 25, 2026

Study contacts

Silvia Villa
Contact
silvia.villa@emn.org
+31 10 268 70 65
Roberto Mina
principal investigator · A.O.U. Città della Salute e della Scienza di Torino
Claudia Stege
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion